Imlunestrant

Imlunestrant is a nonsteroidal antiandrogen (NSAA) that is under development for the treatment of hormone receptor-positive breast cancer. It is being developed by Radius Health and is currently in the phase III clinical trials.

Mechanism of Action[edit | edit source]

Imlunestrant works by binding to the androgen receptor (AR), thereby preventing the activation of the AR pathway. This pathway is crucial for the growth and survival of certain types of breast cancer cells. By blocking this pathway, Imlunestrant can potentially slow down or stop the growth of these cancer cells.

Clinical Trials[edit | edit source]

The effectiveness of Imlunestrant is currently being evaluated in phase III clinical trials. These trials involve patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. The trials are designed to compare the effectiveness of Imlunestrant with that of other standard treatments for this type of cancer.

Side Effects[edit | edit source]

As with any medication, Imlunestrant may cause side effects. These can include nausea, vomiting, fatigue, and hot flashes. However, not everyone who takes Imlunestrant will experience these side effects, and they may be manageable with appropriate medical intervention.

Future Directions[edit | edit source]

If the ongoing clinical trials prove successful, Imlunestrant could become a new treatment option for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Further research is also needed to determine whether Imlunestrant could be effective in treating other types of cancer.